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Abstract
Treatment options in multiple myeloma (MM) are increasing with the introduction of complex multi-novel-agent-
based regimens investigated in randomized clinical trials. However, application in the real-world setting, including
feasibility of and adherence to these regimens, may be limited due to varying patient-, treatment-, and disease-related
factors. Furthermore, approximately 40% of real-world MM patients do not meet the criteria for phase 3 studies on
which approvals are based, resulting in a lack of representative phase 3 data for these patients. Therefore, treatment
decisions must be tailored based on additional considerations beyond clinical trial efficacy and safety, such as
treatment feasibility (including frequency of clinic/hospital attendance), tolerability, effects on quality of life (QoL), and
impact of comorbidities. There are multiple factors of importance to real-world MM patients, including disease
symptoms, treatment burden and toxicities, ability to participate in daily activities, financial burden, access to
treatment and treatment centers, and convenience of treatment. All of these factors are drivers of QoL and treatment
satisfaction/compliance. Importantly, given the heterogeneity of MM, individual patients may have different
perspectives regarding the most relevant considerations and goals of their treatment. Patient perspectives/goals may
also change as they move through their treatment course. Thus, the ‘efficacy’ of treatment means different things to
different patients, and treatment decision-making in the context of personalized medicine must be guided by an
individual’s composite definition of what constitutes the best treatment choice. This review summarizes the various
factors of importance and practical issues that must be considered when determining real-world treatment choices. It
assesses the current instruments, methodologies, and recent initiatives for analyzing the MM patient experience.
Finally, it suggests options for enhancing data collection on patients and treatments to provide a more holistic
definition of the effectiveness of a regimen in the real-world setting.
Introduction
Today’s physicians treating multiple myeloma (MM) are
faced with the challenge of individualizing treatment
choices associated with the highly diverse patient popu-
lations seen across all treatment settings. Historically,
median overall survival (OS) for MM patients was only ~3
years1, and there were a limited number of agents/regi-
mens available. Now there is an increasing range of highly
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active treatment options available, offering novel combi-
nations and leading to the marked improvements in
patient outcomes seen in randomized clinical trials over
the past 15 years2. These changes in the MM treatment
landscape make the current scenario much more com-
plex, requiring physicians to weigh varying goals of
treatment in different settings3–5. The objectives of this
review are to provide a comprehensive summary of the
key factors that determine treatment goals and drive
treatment choices for patients—specifically, therapy-
related factors impacting patient-reported outcomes
(PROs) that are additional to those related to commonly
administered agents and other supportive pharmacologic
interventions—and to summarize existing and emerging
methodologies for capturing these drivers of treatment
choices.
The gap between the clinical-trial and real-world
settings
Phase 3 studies remain the ‘gold standard’ for obtaining
regulatory approvals, based on their strong internal
validity, prespecified and well-defined endpoints, and use
of randomization, blinding and control arms. Favorable
efficacy and benefit:risk balances have been demonstrated
in clinical trials for multiple new standard-of-care regi-
mens in recent years. However, these prospective studies
have limitations in terms of external validity and gen-
eralizability. Frequently, these clinical-trial data are first
reported after a median follow-up of 1–2 years, and thus
the ability of patients to continue treatment beyond the
initial period is unknown. The increasingly complex
novel-agent-based regimens are typically associated with
toxicity additional to that arising from standard backbone
agents such as dexamethasone, and in the real-world
setting the feasibility of and adherence to these regimens
may be more difficult. The full benefit may not be derived
if drugs and regimens are not: (i) tolerable enough for
real-world patients and may thus impact their quality of
life (QoL), including for specific patient populations such
as elderly/frail patients; (ii) available to patients, e.g., due
to limited mobility or travel issues/preference, or due to
affordability; or (iii) in line with patients’ preferences.
There is a need for efficacious options that meet these
criteria, and physicians require a balance of all relevant
information when making treatment decisions.
Additionally, phase 3 studies may include an unrepre-
sentative patient population. Many real-world and registry
studies have concluded that approximately 40% of MM
patients in the real world do not meet the criteria for
inclusion in phase 3 studies on which approvals are based
(Table 1)6–11. Patients may be ineligible for a range of
reasons, including poor performance status, inadequate
organ function, and adverse medical history or comor-
bidities, meaning that they are underrepresented in phase
3 clinical trials. As documented by these studies, clinical
trial ineligibility is often associated with significantly
poorer outcomes compared to those reported in trial-
eligible patients, including shorter progression-free sur-
vival (PFS) and OS (Table 1)6–11. This leads to a lack of
representative phase 3 trial data for this high proportion
of real-world patients.
Additional considerations in real-world patients
In patients who are underrepresented in phase 3 clinical
studies, treatment decisions must be based on additional
considerations. We review multiple factors in addition to
the traditional definition of efficacy that are key when
considering the real-world MM patient experience
(Fig. 1)12–14, including PROs. Those that may affect a
patient’s health-related QoL in the real-world setting
include their disease symptoms and how they are con-
trolled, including supportive care, adverse events (AEs)
associated with therapy, and pre-existing comorbidities.
Also important to patients is their ability to participate in
daily activities, the support available to them, access to
treatment, and—particularly for elderly/frail patients—
access to treatment centers12–14. The level of data cap-
tured on such patient-focused outcomes is another lim-
itation of prospective phase 3 clinical studies.
We highlight that the relative importance of these dif-
ferent factors, and the goals of treatment, differ between
patient groups and treatment settings—suggesting that
‘efficacy’ does not necessarily mean the same thing to
different patients and depends on the balance of all
attributes of a drug or regimen. In this context, a holistic
needs assessment is valuable for making treatment choi-
ces, with broad support from a multidisciplinary team in
the clinic and at home, and will assist in defining efficacy/
effectiveness for each individual patient15,16. Additionally,
in order to fully capture the patient’s experience of their
MM treatment, it is necessary to be able to analyze and—
where feasible—quantify all the relevant real-world dri-
vers; we therefore also review the various instruments and
studies developed to capture treatment impact/burden
and preferences.
Factors of importance to patients in the real-world
setting
Symptom burden
Among the hematologic malignancies, MM patients
have the greatest symptom burden17. Symptoms related to
the CRAB criteria (hypercalcemia, renal impairment,
anemia, and bone disease) can be debilitating and may
require supportive therapy such as bisphosphonates or
denosumab18. These symptoms, along with fatigue, pain,
gastrointestinal symptoms16,19–21, and other common
disease-related complications such as neuropathic symp-
toms, as well as side effects that may arise from supportive
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therapy, can result in MM patients having significantly
impaired QoL compared to the general popula-
tion16,19,20,22–24. This highlights the need for rapid
symptom control and minimal toxicity when choosing a
treatment. However, in many clinical trials, patients with
only biochemical progression are overrepresented.
Side effects
Real-world studies of patients’ preferences have high-
lighted side effects of treatment as an important con-
sideration. Various specific toxicities have been identified
as being associated with specific agents, including per-
ipheral neuropathy with bortezomib25 and thalidomide26,
fatigue with lenalidomide27, cardiovascular side effects
with carfilzomib28,29, gastrointestinal and hematologic
side effects with ixazomib30,31, lenalidomide26,32 and
panobinostat33,34, and fluid-retention effects, bone loss,
eye complications and insomnia with corticosteroids16,
with associated QoL decrements having been reported
due to some of these toxicities. Real-world analyses have
identified the substantial role played by toxicities in
treatment discontinuation in both the frontline set-
ting35,36 and more so in later lines36, suggesting that
toxicities are more burdensome and limit the duration of
treatment more substantially in the real-world setting
compared with pivotal phase 3 studies. Such shortening of
treatment duration due to toxicity has been shown to
adversely impact outcomes37, highlighting how safety is
an important component of efficacy.
Daily activities
Multiple reports have demonstrated the value to
patients of being able to continue with activities of daily
living and of maintaining good physical and mental well-
being. Impairment of activities of daily living due to MM
and its treatment or other comorbidities is associated
with poorer prognosis, as demonstrated by analyses of
outcomes according to frailty indices38,39, as well as
patient frustration40. The ability to continue with one’s
daily routine and physical activities while receiving
treatment is associated with fewer side effects and lower
fatigue and is appreciated by patients as it improves
QoL41–43.
These findings highlight the importance of gathering
PROs in the context of considering the efficacy of a
treatment regimen and taking into consideration the value
patients place on being able to continue with their regular
lives as much as possible. The associated mental health
and well-being of the patient should be considered
too14,44, as adverse impacts on a patient’s activities and
emotional functioning may curtail treatment duration and
effectiveness.
Financial toxicity
Another aspect of concern to MM patients is the cost of
treatment12,14,21,44–47, although the importance of this
varies substantially worldwide according to healthcare
system and access to drugs. Financial hardship may result
from direct out-of-pocket costs arising from treatment
and its side effects, depending on the healthcare system,
and other indirect costs such as those involved in
attending appointments (e.g., travel costs) and any com-
pensation loss arising from impaired ability to work46,47.
Studies have shown that such issues impact patients’
QoL12,14,44. Thus, treatment effectiveness may also be
dependent on a patient’s ability to cope with the financial






















Fig. 1 Treatment factors of importance to MM patients. There are multiple factors of importance to MM patients regarding their treatment that
impact on the effectiveness of that treatment in the real-world setting.
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Treatment convenience/route of administration
Of related importance to patients is the convenience of
treatment. While some patients may value the regular
face-to-face contact with their treating physician/care
team required with parenterally administered medica-
tions, some prefer oral medications even in the context of
shorter progression-free time and/or more AEs48. This
may be driven by various reasons; for example, patients
may not be able to travel to infusion centers for treatment,
due to limited mobility or distance from the clinic, they
may wish to avoid the clinic/hospital setting due to spe-
cific circumstances, or they may want to minimize treat-
ment burden associated with frequent hospital/clinic
visits. Recent analyses have indicated patients’ preference
for oral treatment is based on greater convenience, less
impairment of daily activities, and less impact on work/
productivity48–51. In this context, the feasibility of
receiving treatment at home may be a relevant con-
sideration, particularly in the current COVID-19 pan-
demic, with some studies showing domestic
administration of therapy in MM patients spared the
burden of repeat hospital transfers, leads to a low rate of
treatment discontinuation52, and substantially
improved QoL.
Different patients, different perspectives: patient
preferences in the real-world setting
Patients are becoming increasingly involved in their
own treatment decision-making53, and their specific pre-
ferences, including the importance they attach to each of
the factors discussed in the previous section, as well as
their overall treatment goals, must be considered when
selecting a regimen54. As MM is a heterogeneous disease
with a heterogeneous patient population, these pre-
ferences and goals of treatment may differ between
patients, depending on multiple patient-related, disease-
related, and treatment-related factors3–5,14,54,55. ‘Efficacy’
therefore means different things to different patients.
Treatment decision-making in the context of personalized
medicine needs to be guided by an individual’s composite
definition of what constitutes an effective treatment, per
their preferences and treatment goals, in order to achieve
the right balance between efficacy, safety, tolerability,
feasibility, QoL, and treatment satisfaction55.
Within a specific patient population, drivers for treat-
ment selection may be more granular in detail. For
example, among younger MM patients, while some
prioritize life expectancy/survival44, a discrete-choice
experiment showed that others value preserving further
treatment options, ‘not always thinking of the disease’,
and treatment-free intervals as important characteristics
of therapy, along with effectiveness56. Additionally,
younger patients have been reported to rank severe or life-
threatening toxicity as a greater concern than mild or
moderate chronic toxicity more frequently than older
patients, associated with the need to continue working
and supporting their families57. However, younger, fitter
patients may opt for an intensive treatment including
stem cell transplantation in order to elicit a very deep
response, improve their QoL, and achieve a lengthy
remission and potential functional cure58.
In contrast, among elderly/frail MM patients, pre-
ferences may differ and factors of importance may be
ranked differently. Frail patients may be older and/or have
more comorbidities than fitter patients, and are at a
greater risk of experiencing non-hematologic toxicity and
of discontinuing treatment for reasons other than pro-
gression/death38. Furthermore, frail patients are less able
to receive and tolerate intensive treatment approaches
intended to induce deep responses59. Thus, for some of
these patients, disease control and maintaining QoL may
be priorities2, with comorbidities and the challenges of
polypharmacy, potential toxicities associated with treat-
ment, and functional limitations potentially weighted
more heavily when making treatment decisions60. Treat-
ment convenience and the ability to continue with daily
activities may be of substantial importance in elderly/frail
patients in the context of potentially receiving longer
term, less-intensive treatment regimens than younger/fit
patients.
As well as differing between groups of patients, pre-
ferences and weighting of factors of importance may also
differ in the same patients at different stages of their
treatment course. For example, among relapsed/refractory
MM patients, a primary concern is the efficacy of their
treatment regimen due to the desire to get their disease
back under control after experiencing relapse. While QoL
in newly diagnosed MM patients may be expected to
increase during/following treatment, at relapse it may be
expected only to stabilize61; therefore, QoL may perhaps
be weighted less heavily when choosing treatment in these
patients. Nevertheless, an underlying consideration for all
treatment choices is that safety and tolerability are con-
sistent drivers for efficacy, as the longer a patient can stay
on treatment, the greater the therapeutic benefit they can
accrue.
Measurement of PROs: analyzing real-world preferences
and factors of importance
In the context of implementing PROs, it is imperative to
explore whether current QoL reporting and PRO meth-
odologies for QoL data62 reflect all the key aspects of
importance to patients and the impacts of novel treat-
ments63. Over the past two decades a range of PRO mea-
sures (PROMs), including the European Organisation for
the Research and Treatment of Cancer Quality of Life
Questionnaire–Core-30 (EORTC QLQ-C30) and MM-
specific (EORTC QLQ-MY20) instruments, among others
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(Table 2), have been developed and validated for MM, and a
number of different types of studies have been evaluated as
ways of capturing patients’ treatment preferences,
experience, and perspectives (Table 3)12–14,44,45,48,56,57,64–67.
Multiple studies have shown the beneficial impact of better
QoL assessed using these PROMs on outcomes in MM,
Table 2 Patient-reported outcome measures (PROMs), physician-completed instruments, and types of studies/patient-
reported experience measures (PREMs) for capturing MM patients’ treatment preferences and factors of importance to
their treatment experience.
Instrument/study type Factors addressed Scope/methodology
EORTC-QLQ-C3068 QoL, including physical and emotional
functioning, symptoms, and toxicity
Financial toxicity
30-Item instrument:
Global Health Status/QoL scale
5 Functional scales (physical, role, cognitive, emotional, social)
3 Symptom scales (fatigue, nausea and vomiting, pain)
6 Single-item scales (appetite loss, diarrhea, dyspnea, constipation,
insomnia, financial impact)
EORTC-QLQ-MY2030 QoL, including physical and emotional
functioning, symptoms, and toxicity
20-Item instrument:





14-Item instrument covering symptoms, impact on physical activities,







19-Question instrument covering 11 specific symptoms and questions







5-Item instrument (mobility, self-care, usual activities, pain/discomfort,
anxiety/depression), plus visual analog scale for Global Health Status
Katz ADL scale38 Physical functioning / activities 6-Item instrument capturing whether a patient can/cannot perform
key self-care activities
Lawton IADL scale38 Physical functioning / activities 8-Item instrument capturing whether a patient can/cannot perform
key routine activities
Brief Pain Inventory Pain and impact on physical functioning /
activities and emotional functioning / QoL
9-Question (short form) or 32-question (long form) instrument
evaluating current, overall, and worst pain experienced, and impact on
activities, mood, and QoL
Stated preference study57 Patient preference Multi-criteria decision analysis study; patients state preferences for a
range of specific attributes of treatment
Direct preference
assessment56,64
Weighting of factors of importance Multi-attribute / multi-characteristic analysis study; patients rate
importance of each attribute / characteristic
Discrete-choice
experiment48,56,64
Patient preference Multi-attribute / multi-characteristic analysis study; patients indicate
treatment preferences between discrete sets of pairs of characteristics
Time-trade-off analysis65 Patient preferences Multi-criteria valuation study; patients provide preferences for a range
of health states for a specific time period or dying, and state the
proportion of remaining time alive they would trade to be in full
health, without a specific state
Value-based framework66,67 QoL Evidence-based frameworks for decision-making, incorporating
differing levels of patient experience data
ADL activities of daily living, EORTC European Organization for Research and Treatment of Cancer, FACT-MM Functional Assessment of Cancer–Multiple Myeloma, IADL
instrumental activities of daily living, MyPOS myeloma patient outcome scale, QLQ-C30/MY20 quality of life questionnaire Core 30 module / Myeloma 20-question
module.
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including OS (Table 3), highlighting that the use of PROMs
in randomized clinical trials in MM provides valuable data.
PROMs are particularly valuable in the context of rando-
mization as this reduces the impact on PROs of differences
in patient-/disease-related factors (although the potential
for positive bias in open-label studies and due to data being
gathered from those patients ‘doing best’ on the therapy
should be acknowledged)22,68–72.
It is possible that some aspects of QoL of importance to
MM patients are not being captured with the current
instruments, e.g., sexual functioning73. Further, QoL data
obtained using these instruments often show limited dif-
ferences between treatment arms, despite significant
efficacy and safety profile differences, or do not reflect
specific troublesome aspects of the safety profile of a
regimen, effects also reported in other malig-
nancies26,61,74. Therefore, it should be questioned whether
these and other currently available tools have sufficient
sensitivity to the aspects that are of most importance to
MM patients’ QoL63. This may be particularly relevant if a
novel agent or regimen is specifically associated with a
toxicity infrequently reported with other agents, e.g.,
peripheral neuropathy with bortezomib or thalido-
mide25,26. In such instances, discrepancies may be seen
between broader and more toxicity-specific PRO tools as
well as between physician-reported and patient-reported
side effects25,75.
These observations have led to an increasing focus on
how to implement PROs routinely and accurately in
clinical practice76, and on developing a set of standardized
outcome measures. Use of a standard set of PROMs
would enable broader consideration of the specific fac-
tors/drivers associated with treatment effectiveness and
the risk:benefit ratio for a specific therapy, thereby
improving treatment decision-making for individual
patients.
A number of initiatives are underway worldwide that
aim to quantify the additional factors associated with
treatment satisfaction in MM73,77. One such initiative, the
IMPORTA project, has developed a suggested core set of
outcome measures and instruments for routine collection
in patients with newly diagnosed MM73, including
Table 3 The importance of PRO data in relation to outcomes in MM.
Study Regimen Setting N PRO data and impact on outcomes
Ludwig et al.22 ITd-I RRMM 90 Significantly longer PFS (median 10.2 vs 6.6 months) and OS (median not reached vs
22.9 months) in patients with higher vs lower (dichotomized around median) Global Health
Status/QoL score on EORTC-QLQ-C30 at baseline
Significantly longer OS (median not reached vs 22.9 months) in patients with higher vs lower
(dichotomized around median) physical functioning score at baseline
Strasser-Weippl
et al.71
– NDMM Psychosocial QoL scores – role functioning, emotional functioning, social functioning,
cognitive functioning – prognostic for OS
Viala et al.72 Bortezomib RRMM 202 15 PRO parameters from the EORTC QLQ-C30, EORTC QLQ-MY24, FACIT-Fatigue, and FACT/
GOG-NTx instruments were significant predictors for mortality on univariate analysis
Fatigue (OR 1.052) and physical functioning (OR 0.964) from EORTC QLQ-C30 were significant
predictors for mortality on multivariate analysis
Predictive power for mortality of clinical variables was increased by addition of PRO variables
PROFILES registry68 – MM 226 EORTC QLQ-C30 summary score associated (HR 0.89) with all-cause mortality in MM patients
Global Health Status/QoL scale (HR 0.90) and physical functioning scale (HR 0.90) also
associated with all-cause mortality in MM patients
SEER-MHOS
analysis70
– Elderly NDMM 521 Self-reported health using the SEER-MHOS instrument dichotomized as ‘high’ or ‘low’
Risk of all-cause (HR 1.32) and MM-specific (HR 1.22) mortality elevated in patients with ‘low’
vs ‘high’ self-reported health
NMSG 4/90
analysis69
MP NDMM 524 Global Health Status/QoL, physical functioning, role functioning, cognitive functioning,
fatigue, and pain domain scores on EORTC QLQ-C30 were statistically significant predictors of
survival on univariate analysis.
Poor physical functioning and cognitive functioning remained significant predictors of
survival on multivariate analysis.
EORTC QLQ-C30/MY20 European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core-30/Myeloma-specific module, FACT-BMT
Functional Assessment of Cancer Therapy – Bone Marrow Transplant instrument, HR hazard ratio, IADL instrumental activities of daily living, ITd-I ixazomib-
thalidomide-dexamethasone plus ixazomib maintenance, KPS Karnofsky performance status, MM multiple myeloma, MP melphalan-prednisone, NDMM newly
diagnosed multiple myeloma, NMSG Nordic Myeloma Study Group, OS overall survival, PFS progression-free survival, PRO patient-reported outcome, QoL quality of life,
RRMM relapsed/refractory multiple myeloma, SEER-MHOS Surveillance, Epidemiology, and End Results – Medicare Health Outcomes Survey; TTP time to progression.
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conventional clinical measures of efficacy and safety plus
multiple PROs covering QoL, preferences, and treatment
satisfaction with a recommended collection schedule for
these outcomes73.
In addition to accurately capturing all factors associated
with treatment satisfaction, frequency of PRO collection is
of importance with regards to capturing data in a timely
manner and maximizing sensitivity to changes in QoL and
patient satisfaction—if the recall window is too lengthy,
treatment impacts over the time period may not be fully
captured. Administration of each PRO instrument needs
to be sufficiently frequent to fully capture patients’
experience. PRO deterioration has been shown to precede
clinical disease progression22,23, and so prospective
observational studies using multiple QoL, preference, and
satisfaction instruments to gather novel information may
aid in routine patient management77,78.
Real-world effectiveness
The definition of efficacy is ‘the ability to produce a
desired or intended result’. In the context of clinical
investigations, efficacy is used to define performance
under ideal, controlled conditions, and primary efficacy
endpoints are typically reported upfront, with secondary
endpoints of safety, tolerability, and PROs providing
support for the utility of novel regimens. In contrast,
effectiveness refers to the performance of a regimen under
real-world conditions. Consideration of PROs and their
potential impact on efficacy may be more critical in the
real-world setting compared to the potentially more
motivating environment of clinical trial participation.
Data from randomized controlled trials may not always
reflect results for patients undergoing treatment in rou-
tine clinical practice, although data on some regimens
indicate that duration of therapy, PFS, and/or time to next
therapy are maintained between real-world non-clinical-
trial data and clinical-trial data79–82, suggesting their
efficacy translates into broader effectiveness83. There are
multiple potential reasons for this ‘efficacy–effectiveness
gap’80,83, and real-world effectiveness is dependent on
multiple other endpoints beyond what is measured in
clinical studies13, all of which must be considered in order
to produce the desired or intended result. This suggests
that, in the absence of head-to-head comparisons in
clinical trials, indirect comparisons of regimens through
the analysis of a single clinical trial efficacy endpoint, as is
often done via network meta-analysis, may not accurately
extrapolate to comparative real-world effectiveness.
Furthermore, differences between clinical trial and real-
world outcomes must be considered in the context of the
heterogeneous healthcare systems that exist between dif-
ferent countries and sometimes within individual coun-
tries. Differences in patient management and MM
specialization between treatment centers may affect
treatment outcomes, associated with factors beyond
conventional efficacy and safety as determined in a clinical
trial80,84. In fact, data on real-world treatment within
specialist networks81 or at specialist MM centers79
demonstrate prolonged outcomes versus, for example,
claims data analyses from broader real-world practice85.
One potential driver for the discrepancy in outcomes
between centers participating in clinical trials and MM
specialist centers, compared to broader real-world prac-
tice, may be the timing of treatment initiation at relapse.
Several studies have shown that delaying treatment until
symptomatic relapse occurs, compared with starting
therapy at biochemical relapse, identified through regular
follow-up and monitoring, may result in poorer out-
comes79,86,87. Additionally, differences in clinicians’
experience with new regimens and in the availability of
infrastructure for monitoring and toxicity management
may also be relevant.
In the context of the above, routine collection of addi-
tional endpoints such as QoL and other PROs88,89, plus
healthcare resource utilization, alongside the key efficacy
and safety data collected in clinical trials, would aid in
providing a complete picture of efficacy of a regimen90–94.
Furthermore, as reviewed recently, there is a need to
improve safety assessment and reporting in various
hematologic malignancies95, with improved data collec-
tion and evaluation aiming to provide additional valuable
information of relevance to the real-world effectiveness of
treatments. An additional element to consider in this
expanded framework of standard data collection on MM
patients is the incorporation of real-world data to aug-
ment the findings of randomized controlled trials. This
would further enhance the datasets available on different
treatment options. More informed decisions could thus be
made between treatments that include clinical trial effi-
cacy and safety data, QoL data, patient preferences and
treatment satisfaction data, economic information, and
other important issues.
Future perspective and recommendations
With our increasing understanding of the differences
between clinical trial patients and real-world populations,
and the apparent gap between clinical trial efficacy and
real-world effectiveness80, there are a number of recom-
mendations that could enhance data collection on MM
treatment regimens in the future (Fig. 2). For clinical trials
there are ongoing initiatives aimed at modifying standard
inclusion and exclusion criteria, for example, by removing
comorbidity restrictions, which will improve the gen-
eralizability of trial findings96,97. Similar initiatives are also
required for defining inclusion criteria for real-world
evidence studies/analyses. Additional considerations
include whether to obtain data from insurance databases
or hospitals, determining the minimal requirements for
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clinical data, and evaluating whether to mimic the
approach of cancer registries by incorporating data from
smaller, non-specialist centers or offices and including all
patients seen in the contributing clinic.
From the perspective of regulatory needs, the parallel
collection of real-world data and clinical-trial data should
be explored in order to provide a broader dataset on
which to consider approval of a regimen. Incorporating
routine assessment of QoL and other PROs within a
broader context of a regimen’s efficacy may prove bene-
ficial in making drugs available to patients more quickly,
as many of these data are of relevance from a regulatory
perspective88,98,99. Another approach that could help
speed up patient access to new regimens would be to
consider parallel post-marketing trials to gather additional
data to augment the dataset initially available for reg-
ulatory submissions. However, in this context it will be
important to explore the current challenges with real-
world data and limitations of real-world studies, and
identify the need for additional or improved datasets from
this setting. For example, data from registries often do not
include all the data required for Health Technology
Assessments, for which extra evidence is then requested.
Across both clinical trials and real-world studies, there
is a need to utilize more PROMs—implementation of a
standardized core set of outcome measures for collection
from MM patients will help in this regard73. Similarly,
data from other ongoing studies will be of interest in
order to determine how best to use such PRO data on
QoL, patient preferences, and patient satisfaction in the
context of patient management and treatment decision-
making77. However, it will be important to consider the
time pressures that healthcare professionals are under in
their daily clinics. Completion of multiple instruments
and/or analysis of multiple PROMs is likely to be too
time-consuming for most, and so collection of a core set
of PRO data will require a practical but comprehensive/
informative tool that does not take too much time to
complete and analyze.
In light of the heterogeneous healthcare systems that
can exist within individual countries, there is also a need
to disseminate information more widely regarding the
optimal management and supportive care of MM patients,
including the value of gathering PROs, along with critical
information on how to utilize different regimens and
agents. Cascading this knowledge from MM specialist
centers to non-specialist practices in which fewer MM
patients are routinely seen will be of value. Outcomes
observed in clinical trials may be impacted by suboptimal
management in the real-world setting100. Thus, addres-
sing this need may help partially close the gap seen
between clinical trial efficacy and real-world effectiveness.
Conclusions
In conclusion, it is important to emphasize that selec-
tion of treatment options requires a review of the indivi-
dual patients’ characteristics along with careful
understanding of the difference between efficacy and
effectiveness, and open, honest communication with
patients to appropriately define their preferences. In the
modern era of MM therapy, with multiple treatment
options in the frontline and relapsed settings, the isolated
use of conventional clinical trial efficacy as a metric for
comparisons between agents/regimens is not optimal.
While efficacy data from randomized clinical trials remain
the gold standard for defining the relative benefit of a
regimen, safety, QoL, and other PROs are important
contributors to a regimen’s effectiveness in the real world.
Regimens that are more tolerable and convenient for
patients and have a positive impact on patients’ QoL may
be more likely to be administered for longer, thus
enabling their effectiveness. For example, development of
subcutaneous or oral instead of intravenous formulations
of agents52,101,102, potentially enabling home administra-
tion52,101, or development of novel therapeutics within a
Broaden inclusion 
criteria / limit 









and define data 
sources, minimal 
data requirements, 




real-world datasets and 
provide consistent 
guidelines for data 
collection in real-world 
studies
Eligibility 
criteria Parallel collection of 
real-world & clinical 
trial data
•Provide a broader 
dataset from which to 
determine the balance 
of a regimen’s efficacy, 
safety, PROs, including 




and other PROs for 
regulatory 
submissions
•Shorten initial approval 
time and enable quicker 




•Augment and broaden 
the dataset initially 







set of outcomes for 
collection from MM 
patients
•Provide more PRO data, 
including QoL data, in a 
consistent manner 










including the value 
of PRO data
•Improve patient care 




Fig. 2 Enhancing MM data collection. Recommendations for
enhancing future data collection on MM treatment regimens. MM,
multiple myeloma; PRO, patient-reported outcome; QoL, quality of life.
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drug class that have lower risks of key toxicities, while
preserving the efficacy, are valuable in this context.
A broader scope of additional endpoints and patient-
related factors must be considered due to their critical
impact on the effectiveness of a treatment in the real
world. Standardizing the collection and reporting of these
endpoints and factors89, together with validation of novel
instruments or composite metrics incorporating these
additional considerations, will enable a broader compar-
ison between different treatment regimens that is more
meaningful to patients in the real-world setting. Eluci-
dating how the weighting of each of the factors con-
tributing to a regimen’s effectiveness differs between
groups of patients may lead to more patient-focused
decision-making for tailored treatment approaches. An
ultimate goal would be deriving a convenient, patient-
friendly way to measure these aspects in an individual
patient in a time-efficient way for physicians.
A final point to emphasize is that going forward it will be
necessary to ensure that patients are more representative
of the real-world MM patient population, both in clinical
trials and in real-world studies/analyses. Such approaches
will further support a comprehensive characterization of
efficacy, safety, and PROs, including impact on QoL,
associated with a treatment regimen in a representative
population, thereby enabling improved treatment
decision-making and personalization of therapy.
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